Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtronicBSP:MDTC34 +1.37%72 Return-on-Tangible-Asset is 12.16% as of Apr. 2026, which is 2% above its 10-year median of 11.93. GuruFocus rates BSP:MDTC34 with a GF Score™ of 72/100 and a GF Value™ of R$247.95 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Medtronic ranks better than 88.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Medtronic's annualizedNet Income for the quarter that ended in Apr. 2026 was R$25,049 Mil. Medtronic's average total tangible assets for the quarter that ended in Apr. 2026 was R$206,074 Mil. Therefore, Medtronic's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2026 was 12.16%.
The historical rank and industry rank for Medtronic's Return-on-Tangible-Asset or its related term are showing as below:
BSP:MDTC34'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.12 Med: 11.93 Max: 15.71
Current: 12.35
During the past 13 years, Medtronic's highest Return-on-Tangible-Asset was 15.71%. The lowest was 9.12%. And the median was 11.93%.
BSP:MDTC34's Return-on-Tangible-Asset is ranked better than 88.42% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs BSP:MDTC34: 12.35
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Medtronic Return-on-Tangible-Asset Related Terms
Medtronic Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Medtronic's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:MDTC34 vs SYK, BSX, EW: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Medtronic's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Medtronic's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.16% mean?
Medtronic (BSP:MDTC34) has a Return-on-Tangible-Asset of 12.16% as of Apr. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medtronic and its competitors. This is near median its historical median of 11.93. Over the past decade, Medtronic's Return-on-Tangible-Asset has ranged from 9.12 to 15.71. According to the industry distribution chart, Medtronic ranks #99 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is Medtronic's Return-on-Tangible-Asset too high?
Medtronic's current Return-on-Tangible-Asset of 12.16% is near median its 10-year median of 11.93. Over the past 10 years, this metric has ranged from a low of 9.12 to a high of 15.71. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Medtronic's value of 12.16% is 1861.3% above this industry median. Based on the distribution chart, Medtronic ranks #99 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medtronic has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Return-on-Tangible-Asset compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #99 out of 855 companies for Return-on-Tangible-Asset. This places Medtronic in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.62. Medtronic's value of 12.16% is 1861.3% above this benchmark. Historically, Medtronic's own Return-on-Tangible-Asset has ranged from 9.12 to 15.71 over the past decade. While the company's 10-year median is 11.93 vs. the industry median of 0.62, Medtronic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current Return-on-Tangible-Asset of 12.16% is 1861.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medtronic and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current Return-on-Tangible-Asset is 12.16%, which is near median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$247.95, compared to a current price of R$209.88 — trading 15.4% below its estimated fair value. The current Return-on-Tangible-Asset is 12.16%, which is near median its 10-year median of 11.93 and 1861.3% above the Medical Devices & Instruments industry median of 0.62. Medtronic's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Return-on-Tangible-Asset is 12.16% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$209.88 is trading 15.4% below its estimated GF Value™ of R$247.95.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for BSP:MDTC34:
Return-on-Tangible-Asset: 12.16% (near median its 10-year median of 11.93)
GF Value™: R$247.95 vs. price of R$209.88 (15.4% below fair value)
Industry Position: 1861.3% above the Medical Devices & Instruments median (#99 of 855)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
72GF Score
Get the complete analysis for BSP:MDTC34
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
